Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): a national, cross-sectional study
Christine Zizzi(Crittenton Hospital Medical Center), Chad Heatwole(Crittenton Hospital Medical Center), Paul Mehta(Agency for Toxic Substances and Disease Registry), Anika Varma(Crittenton Hospital Medical Center), Jamison Seabury(Crittenton Hospital Medical Center), Joanne Wuu(University of Miami), Volkan Granit(Biohaven Pharmaceuticals (United States)), John Heatwole(Sutherland Hospital), Michael Benatar(University of Miami), Danae Alexandrou(Crittenton Hospital Medical Center), Ellen Wagner(Crittenton Hospital Medical Center), James B. Caress(The University of Texas at San Antonio Health Science Center), Jeffrey Statland(The University of Texas at San Antonio Health Science Center), Richard Bedlack(Duke University), Jennifer Weinstein(Crittenton Hospital Medical Center), Spencer Rosero(Crittenton Hospital Medical Center), Nuran Dilek(MACOM (United States))
Cited by 29
Related Papers
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
|The Lancet Neurology|2023|255
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
|Neurology|2020|201
Pesticide exposure and amyotrophic lateral sclerosis
|NeuroToxicology|2012|164